Filing Details
- Accession Number:
- 0000950170-25-091759
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2025-06-30 17:49:25
- Reporting Period:
- 2021-12-29
- Filing Date:
- 2025-06-30
- Accepted Time:
- 2025-06-30 17:49:25
- Original Submission Date:
- 2022-01-03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1855608 | Hannah Valantine | C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304 | No | No | No | No |
Transaction Summary
| Purchased: | 1,752 shares | Avg. Price: $14.24 | Total Value: $24,948.48 |
| Number of Shares After Transactions: | 3,294 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-12-29 | 1,752 | $14.24 | 3,294 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,687 | Indirect | By Spouse |
Billionaire Hedge Funds
